References
- Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. 2001. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 40(6):411–426.
- Bessire AJ, Ballard TE, Charati M, Cohen J, Green M, Lam MH, Loganzo F, Nolting B, Pierce B, Puthenveetil S, et al. 2016. Determination of antibody–drug conjugate released payload species using directed in vitro assays and mass spectrometric interrogation. Bioconjug Chem. 27(7):1645–1654.
- Bruins AP, Weidolf LO, Henion JD, Budde WL. 1987. Determination of sulfonated azo dyes by liquid chromatography/atmospheric pressure ionization mass spectrometry. Anal Chem. 59(22):2647–2652.
- Chan TS, Scaringella YS, Raymond K, Taub ME. 2020. Evaluation of Erythromycin as a tool to assess CYP3A contribution of low clearance compounds in a long-term hepatocyte culture. Drug Metab Dispos. 48(8):690–697.
- Cuykens F. 2018. Mass spectrometry in drug metabolism and pharmacokinetics: current trends and future perspectives. Rapid Commun Mass Spectrom. 33:90–95.
- Darnell M, Weidolf L. 2013. Metabolism of xenobiotic carboxylic acids: focus on coenzyme A conjugation, reactivity, and interference with lipid metabolism. Chem Res Toxicol. 26(8):1139–1155.
- Davis JA, Rock DA, Wienkers LC, Pearson JT. 2012. In vitro characterization of the drug–drug interaction potential of catabolites of antibody-maytansinoid conjugates. Drug Metab Dispos. 40(10):1927–1934.
- Dubbelman AC, Cuyckens F, Dillen L, Gross G, Vreeken RJ, Hankemeier T. 2018. Mass spectrometric recommendations for Quan/Qual analysis using liquid-chromatography coupled to quadrupole time-of-flight mass spectrometry. Anal Chim Acta. 1020:62–67.
- Hultman I, Vedin C, Abrahamsson A, Winiwarter S, Darnell M. 2016. Use of HμREL human coculture system for prediction of intrinsic clearance and metabolite formation for slowly metabolized compounds. Mol Pharm. 13(8):2796–2807.
- Husser C, Brink A, Zell M, Müller MB, Koller E, Schadt S. 2017. Identification of GalNAc-conjugated antisense oligonucleotide metabolites using an untargeted and generic approach based on high resolution mass spectrometry. Anal Chem. 89(12):6821–6826.
- King L, Kotian A, Jairaj M. 2014. Introduction of a routine quan/qual approach into research DMPK: experiences and evolving strategies. Bioanalysis. 6(24):3337–3348.
- Li XQ, Hayes MA, Grönberg G, Berggren K, Castagnoli N, Jr, Weidolf L. 2016. Discovery of a novel microsomal epoxide hydrolase-catalyzed hydration of a spiro oxetane. Drug Metab Dispos. 44(8):1341–1348.
- Lin C, Khetani SR. 2016. Advances in engineered liver models for investigating drug-induced liver injury. Biomed Res Int. 2016:1–20.
- Myler H, Rangan VS, Wang J, Kozhich A, Cummings JA, Neely R, Dail D, Liu A, Wang B, Vezina HE, et al. 2015. An integrated multiplatform bioanalytical strategy for antibody-drug conjugates: a novel case study. Bioanalysis. 7(13):1569–1582.
- Schaefer M, Morinaga G, Matsui A, Schänzle G, Bischoff D, Süssmuth RD. 2018. Quantitative expression of hepatobiliary transporters and functional uptake of substrates in hepatic two-dimensional sandwich cultures: a comparative evaluation of Upcyte and primary human hepatocytes. Drug Metab Dispos. 46(2):166–177.
- Smith S, Lyman M, Ma B, Tweedie D, Menzel K. 2021. Reaction phenotyping of low-turnover compounds in long-term hepatocyte cultures through persistent selective inhibition of cytochromes P450. Drug Metab Dispos. 49(11):995–1002.
- Umehara K, Cantrill C, Wittwer MB, Di Lenarda E, Klammers F, Ekiciler A, Parrot N, Fowler S, Ullah M. 2020. Application of the extended clearance classification system (ECCS) in drug discovery and development: selection of appropriate in vitro tools and clearance prediction. Drug Metab Dispos. 48(10):849–860.
- Weidolf L, Andersson T, Bercu JP, Brink A, Glowienke S, Harvey J, Hayes MA, Jacques P, Lu C, Manevski N, et al. 2020. Qualification of impurities based on metabolite data. Regul Toxicol Pharmacol. 110:104524.
- Weidolf L, Borg KO, Hoffmann KJ. 1984. Urinary metabolites of felodipine, a new vasodilator drug, in man, dog, rat and mouse. Xenobiotica. 14(8):657–666.
- Weidolf L, Karlsson KE, Nilsson I. 1992. A metabolic route of omeprazole involving conjugation with glutathione, identified in the rat. Drug Metab Dispos. 20(2):262–267.
- Weston DJ, Weidolf L. 2012. Conference Report: High-resolution MS in drug discovery and development: current applications and future perspectives. Bioanalysis. 4(5):481–486.